Invitae, a medical genetics company, agreed to acquire Clear Genetics, a developer of software for providing genetic services at scale, for $50m. "Clear Genetics' technologies have been designed to meet the needs of clinicians. In some ways, they can be thought of as a digital navigator for using genetic testing to care for patients. Clear Genetics, like Invitae, developed these tools with the goal of ensuring easier access to medically responsible, actionable genetic testing. Understanding how best to expand the use of these technologies will play an important role in answering how clinicians will harness the power of genetics in mainstream medicine," Robert Nussbaum, Invitae chief medical officer.